Based on PubMed | In endometrial cancer, can tingling sensations (paresthesia) occur, and if present, do they have any prognostic significance?

In endometrial cancer, tingling sensations in the hands or feet (paresthesia) can occur, most commonly as a side effect of standard treatments such as taxane- and platinum‑based chemotherapy (for example, paclitaxel and carboplatin). ^{[1] [2]} Paresthesia can also arise rarely as part of a paraneoplastic neurological syndrome (an immune‑mediated nerve disorder triggered by the tumor), but this is uncommon in endometrial cancer. ^[3] In current evidence, paresthesia itself generally reflects treatment toxicity rather than the cancer’s aggressiveness, so it typically does not serve as a direct prognostic marker for survival; instead, it is used to guide dose adjustments and supportive care. ^[4]

Why tingling can happen

• Chemotherapy-induced peripheral neuropathy: Paclitaxel and platinum agents frequently cause neuropathy with symptoms like tingling, numbness, and burning pain in a “glove and stocking” pattern affecting fingers and toes. ^{[1] [2]} Patient education resources for these regimens specifically warn about tingling and numbness and advise reporting symptoms promptly. ^{[5] [6]} Adding paclitaxel to cisplatin/doxorubicin in advanced endometrial cancer increased patient‑reported neuropathy (particularly sensory symptoms) compared with cisplatin/doxorubicin alone. ^[7]

• Less common immune‑related or paraneoplastic causes: Rare case reports describe endometrial carcinoma presenting with painful paresthesias due to paraneoplastic sensorimotor polyneuropathy, sometimes associated with vasculitis, which can improve when the primary tumor is treated and with immunosuppression. ^[3] Reviews of uterine cancer note a spectrum of neurological paraneoplastic syndromes, but these are uncommon overall. ^[8]

Does paresthesia have prognostic significance?

• As a marker of cancer behavior: There is no robust evidence that the presence or severity of paresthesia independently predicts recurrence risk or overall survival in endometrial cancer. ^[9] Available prognostic models for advanced stages emphasize disease spread (for example, peritoneal metastases and positive peritoneal cytology) rather than neurologic symptoms like tingling. ^[9]

• As a marker of treatment exposure and tolerability: Paresthesia is more clearly related to the type and intensity of chemotherapy received (taxanes and platinums); higher neuropathy rates are seen with these first‑line regimens compared with non‑taxane/non‑platinum therapies. ^[10] Patient‑reported neuropathy is worse with regimens that include paclitaxel, and while it often improves months after therapy, it may persist in some individuals. ^[7] Providers use neuropathy grades to delay treatment or reduce dose when symptoms are significant, which can influence treatment delivery but not necessarily long‑term cancer outcomes by itself. ^[4]

• Quality of life implications: Chemotherapy‑induced neuropathy in gynecologic cancers is common and meaningfully lowers quality of life and daily functioning, highlighting the need for early recognition and management, even if it does not directly predict survival. ^[11]

Practical management implications

• Report symptoms early: Educational materials for common endometrial cancer regimens advise notifying the care team about tingling or numbness to prevent injuries and allow timely dose adjustments. ^{[1] [5]}

• Treatment adjustments: Clinical protocols recommend delaying or reducing dose when neuropathy reaches moderate severity at the start of a cycle to limit progression of symptoms. ^[4]

• Rehabilitation and safety: Supportive care (for example, physical therapy and home safety measures) can help with balance, grip, and fall prevention while neuropathy improves. ^{[12] [13]}

• Rare paraneoplastic patterns: When tingling is asymmetric, rapidly progressive, or accompanied by weakness and pain out of proportion to typical chemo effects especially if occurring before treatment clinicians may consider paraneoplastic neuropathy and evaluate for immune‑mediated mechanisms. ^{[3] [8]}

Key takeaways

• Paresthesia is common during and after standard chemotherapy for endometrial cancer and usually reflects treatment‑related peripheral neuropathy rather than tumor progression. ^{[1] [2]}
• Current evidence does not support tingling as an independent prognostic marker for survival; established prognostic factors focus on disease extent rather than neuropathic symptoms. ^[9]
• The presence and severity of paresthesia are more predictive of treatment exposure (especially taxane‑platinum regimens) and may prompt dose modifications to balance efficacy and nerve safety. ^{[7] [4]}
• Rarely, tingling can signal a paraneoplastic neuropathy linked to the cancer’s immune effects; in such cases, symptom course may correlate with tumor control. ^[3]

---

Quick reference: paresthesia in endometrial cancer

Aspect	What it usually indicates	How common	Prognostic meaning
During/after paclitaxel–carboplatin	Chemotherapy-induced neuropathy	Common; widely recognized in patient materials for these regimens	Not an independent survival marker; guides dose/schedule adjustments
With cisplatin/doxorubicin vs + paclitaxel	Higher neuropathy with paclitaxel added	Patient-reported neuropathy significantly worse with paclitaxel	Reflects regimen neurotoxicity, not tumor aggressiveness
Before therapy or atypical pattern (asymmetric, vasculitic)	Possible paraneoplastic neuropathy	Rare case reports	May track with tumor control but not validated as a general prognostic factor

^{[1] [2] [7] [3] [8] [4]}